viewArix Bioscience PLC

Arix Bioscience Plc - Dr Roberto Iacone appointed as EiR

Arix Bioscience plc

Arix namesDr as Entrepreneur in ResidenceRoberto Iacone

New role extends collaboration with to identify opportunities for early stage investment and creation of biotechnology companiesTakeda Ventures

(LSE:ARIX) ("Arix"), a global venture capital company focused on investing in and building breakthrough biotech companies today announced the appointment of Dr. as Entrepreneur in Residence (“EiR”). In his new role, Roberto will focus on company creation, sourcing early stage European investment opportunities that Arix will jointly fund with its partner, the strategic venture investing arm of ., :LONDON9 March 2020Arix Bioscience plcTakeda Ventures, Inc.Takeda PharmaceuticalsRoberto Iacone

Roberto has over 15 years’ experience in the life sciences sector. He joins Arix from his role as EiR at where he was involved in the successful founding of new companies, including Black Diamond Therapeutics, where he served as VP Biology. Previously, Roberto was the Director and Global Head of the Rare Diseases Research Division at Roche, where he was employed for 10 years. During his tenure at Roche, he was responsible for generating disease area strategies and advancing several assets for immunological and neurological disease from discovery to early clinical development, which included both large and small molecule programs. He obtained his MD/PHD from the and .Versant VenturesMax Planck InstituteUniversity of Naples Federico II

“I am delighted to welcome Roberto to the investment team. Roberto brings a wealth of international experience and excellent track record of creating companies that foster exciting science. He will be a valuable addition to Arix and as we work together to create innovative new companies that address serious medical need.”  , Chief Executive Officer, commented:Joe AndersonTakeda

, Head of commented:Mike MartinTakeda Ventures

“Takeda has a leading partnership model that values external collaboration to unlock innovation no matter where it resides. My colleagues and I look forward to working with Roberto and the rest of the team at Arix to identify exciting opportunities to create early-stage companies that could one day deliver transformational medicines to patients.”

“Arix has a superb portfolio of innovative companies and I am very excited to be working with such an experienced investment team. The partnership with is a fantastic opportunity for both companies to work together to build exciting biotech companies and their respective pipelines.”commented:Roberto IaconeTakeda

Roberto will be the second Entrepreneur in Residence at Arix after based , who joined in .  Roberto will be based in .MunichBaselChristian SchetterDecember 2018



For more information, please contact:

, Head of Investor Relations +44 (0)20 7290 1072   Arix Bioscience plc

Charlotte Parry[email protected]

Mary Clark, , +44 (0)20 3950 9144Optimum Strategic Communications

Supriya MathurShabnam Bashir[email protected]

AboutArix Bioscience Plc

is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.Arix Bioscience plc

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.


Quick facts: Arix Bioscience PLC

Price: 95.5

Market: LSE
Market Cap: £129.45 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018